MTOR and melanoma: The melanoma-derived AKT1-carrying melanosome is released and transmitted to TAMs via dermal fibroblasts, inducing VEGF secretion in an mammalian target of rapamycin (mTOR)-dependent manner and polarization of macrophages toward a pro-tumor phenotype; this phenotypic shift has been associated with resistance to immunotherapy in melanoma (88).